Our Oncoscreen Parpmatch is used primarily for indications involving deficiencies in the Homologous Recombination Repair (HRR) pathway. It covers 72 genes associated with the HRR pathway, including BRCA1/2, PALB2, RAD, and ERCC2-4. Specifically designed for PARP inhibitors, this panel is available for the diagnosis of both tissue and blood-based samples. As it focuses on genes relating to the HRR pathway, its applications extend primarily to ovarian,lung, breast, and prostate cancer. The FDA approved the first PARP inhibitor, Olaparib in 2014 for patients with germline BRCA1/2 mutations who have pretreated ovarian cancer, and the agency has since broadened indications for PARP inhibitors in terms of disease settings. Assays that measure HRD status caused by different mechanisms are now the central focus. In May 2020, the FDA also approved Olaparib for patients with metastatic castration-resistant prostate cancer with somatic or germline HRR mutations. Currently, it is being used for biomarker detection in the clinical trials of LYNPARZA® (olaparib), L-MOCA, and Profound.
In addition, Burning Rock has licensed the exclusive rights to Myriad’s MyChoice+ assay for usage in China. Myriad’s MyChoice+ is an assay analyzing loss of heterozygosity, telomeric allelic imbalance, and large scale state transitions to produce a comprehensive assessment of one’s HRD status, otherwise known as HRD score.
The HRD panel comes in 2 versions, The 72 gene or comprehensive 520 gene panel. The benefit with the larger panel is additional complex biomarkers such as TMB and MSI, in addition to other biomarkers. Our 520 panel shows outstanding performance in AZ’s L-MOCA study.